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Research article  
Quality of life in Romanian patients with 
schizophrenia based on gender, type of 
schizophrenia, therapeutic approach, and 
family history   
 Elena Alina Roșca1,2*, Ovidiu Alexinschi3, Călin Brîncuș2, Valentin Petre Matei1,2, Ana 
Giurgiuca1,2  
 
1Carol Davila University of Medicine and Pharmacy, Department of Psychiatry, Bucharest, Romania  
2Alexandru Obregia Clinical Hospital of Psychiatry, Department of Psychiatry, Bucharest, Romania  
3Socola Institute of Psychiatry, Socola, Romania 
  
Abstract The low quality of life of patients with schizophrenia has been extensively discussed and 
investigated. Various aspects from gender, socio-demographic profile, and/or type of neuroleptic 
treatment have been taken into account in describing this condition. The purpose of this study is 
to assess the perceived quality of life of Romanian patients suffering from schizophrenia and to 
correlate it with gender differences, type of schizophrenia, family history of psychiatric illness, 
and type of antipsychotic treatment. 143 patients diagnosed with schizophrenia according to DSM 
IV-TR and ICD 10 were included in the study. Social demographic data were documented and 
further assessment was performed using the Subjective Well Being under Neuroleptic Treatment 
Scale –the short form (SWN-S) and the short version of the WHO- Questionnaire for The Quality 
of Life (WHO-QoL-BREF). The mental functioning dimension was higher in men than women; 
the social integration dimension was higher for the residual type of schizophrenia. Emotional 
regulation and the capacity of social integration did not show significant differences between 
patients who had a family history of mental illness and those who did not. Levels of self-control 
and physical functioning were better for patients treated with atypical antipsychotics and who did 
not report a family history of psychiatric illness. All five dimensions of the SWN-S were higher 
in patients treated with atypical antipsychotics, compared to those who were treated with typical 
antipsychotics. The study showed that for people with schizophrenia mental functioning was 
better preserved in men, in patients who did not have a family history of psychiatric illness, and 
in patients who were treated with atypical antipsychotics. The level of social integration was 
better in patients who were treated with atypical antipsychotics but this effect depended on the 
type of schizophrenia.    
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Highlights ✓ The level of social integration, self-control and physical function is better in subjects who 
are treated with atypical neuroleptics. 
✓ Self-control, physical function and the capacity of emotional control is equally affected 
in both women and men with, while mental functioning would be better preserved in men. 
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Introduction 
Quality of life is a construct represented by an 
individual’s subjective perception of his/her self in 
relation to his place and existence/ adaptation in life, 
judged according to a cultural, social, and personal 
system of values (generally governed by objectives, 
expectations, standards, etc.) (1). 
Schizophrenia is a disabling chronic psychiatric 
illness which affects most (if not all) major fields of 
mental functioning. The disease is equally prevalent in 
both men and women. However, the onset and course of 
illness differs between the two genders. Women show 
an incidence peak for schizophrenia between 21 and 25 
years, compared to 25-32 for men, and women also 
show a second incidence peak in the fourth decade of 
life (2, 3).  
Several studies have shown that the quality of life 
of female patients suffering from schizophrenia takes a 
smaller toll compared to male patients, probably due to 
a reduced number of hospital admissions, lower doses of 
medication for women, and generally faster remissions 
(4, 5). Considering long-term prognosis, however, the 
research literature indicates a slight trend toward poorer 
outcomes in female patients (6). Regarding other 
differences, men tend to be more predisposed to 
substance abuse and anti-social behaviors (4, 7), 
whereas women are more prone to symptoms from the 
affective spectrum (8). 
Quality of life has become a major area of interest 
due to the disabling aspect of schizophrenia. In addition, 
it is well known that schizophrenia and schizophrenia-
related disorders present an increased incidence among 
the first-degree relatives of patients who suffer from this 
illness (9). 
The neuroleptic medication used to treat 
schizophrenia consists of two broad categories: typical 
and atypical antipsychotics. Although the available 
drugs have a wide array of pharmacological properties, 
generally all these drugs have the capacity to antagonize 
postsynaptic dopamine receptors in the brain. Dopamine 
and the quality of life are mutually linked through the 
brain’s reward system. Further assessment of the quality 
of life needs to take in account the type of drug used, 
even though all relevant drugs share a common final 
endpoint (9).  
Materials and Methods 
One hundred and forty-three patients were included 
in this study, being admitted in “Prof. Dr. Alexandru 
Obregia” Clinical Hospital of Psychiatry during a 3-year 
period (2009-2012). The diagnosis of schizophrenia was 
established according to DSM- IV-TR (10) and ICD 10 
(11) criteria. Patient ages ranged from 18 to 65 years, 
and 58.7% were female. 
More than three quarters of the sample was 
diagnosed with paranoid schizophrenia (75,5%), 14,7% 
with undifferentiated schizophrenia, 5,6 % with residual 
schizophrenia, and 4,2% with hebephrenic 
schizophrenia. Because patients diagnosed with simple 
schizophrenia made up only 0,9 of the sample (1 case), 
this segment was not included in the analysis. 
Most subjects included in the lot (60,8%) did not 
have a family history of psychiatric illness. 86,3% of the 
patients diagnosed with schizophrenia and included in 
the lot followed a treatment plan based on an atypical 
neuroleptic, while only 13,7% of them received 
treatment with a typical neuroleptic. 
All patients were undergoing antipsychotic 
treatment for at least 4 weeks before admission. The 
study was approved by the Ethics Committee of the 
“Prof. Dr. Alexandru Obregia” Clinical Hospital of 
Psychiatry, Romania. Patients also received an informed 
consent form and given time to consider participation; 
all concerns were addressed before obtaining their 
signed approval. 
Clinical variables and psychological parameters 
were evaluated using the following standardized scales:    
• Subjective Well-being under Neuroleptic 
Treatment Scale (SWN) (12-14), a self-assessment scale 
with the initial form of 38 items and a short variant of 
20 items (10 negative and 10 positive scored items), 
each being scored on a Likert 6-step scale. The purpose 
of the scale is to show the subjective experience of the 
patient during neuroleptic treatment, having 5 distinct 
topics: physical functioning, mental functioning, self-
control, emotional regulation, and social integration. A 
high value indicates better functioning of the patient on 
the respective domain. The scale has an overall 
evaluation of both the efficiency and the quality of the 
medical treatment in schizophrenia, but it also includes 
the subjective well-being of the respondents, and further 
offers the possibility of evaluating the subjective 
perception of the patient, no matter the psychopathology 
(15, 16). 
• World Health Organization Quality of Life (WHO-
QoL – BREF) (17-19); in our analysis, we used scores 
related to 4 domains of quality of life (physical, 
psychological, social, and living environment), while 2 
other items were evaluated separately. The patients’ 
answers were quantified using a 5-step Likert scale. 
High values correspond to a high level of satisfaction 
regarding quality of life (20-22).     
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Statistical processing was performed using the IBM 
SPSS Statistics 20 program (23, 24). A specific 
objective of our study was to investigate several tests/ 
results between distinct lots, created according to 
gender, type of schizophrenia, type of antipsychotic 
used, and family history of psychiatric illness. For this 
purpose, inferential statistics were used, namely 
parametric difference tests (“t” tests and ANOVA) or 
non-parametric tests (Chi square); we opted to use 
parametric tests when possible as they are more 
powerful statistically.   
Results 
1. Differential aspects of SWN-S in schizophrenia 
patients. 
1.1 SWN-S and gender differences 
 The means and standard deviations for the two 
genders on each test dimension are represented in Table 1. 
Table 1. SWN-S subscale values according to 
gender 
 
Gender N Mean Std. 
Deviation 
Std. Error 
Mean 
Mental 
functioning 
 Woman 84 10,692 3,5901 ,3905 
Man 59 11,978 3,9007 ,5100 
Self-control 
Woman 84 11,123 3,8961 ,4238 
Man 59 12,311 3,0507 ,3989 
Physical 
functioning 
Woman 84 11,831 4,5181 ,4915 
Man 59 12,667 4,1994 ,5490 
Emotional 
regulation 
Woman 84 12,477 5,0069 ,5447 
Man 59 11,889 4,1081 ,5371 
Social 
integration 
Woman 84 10,569 4,3901 ,4776 
Man 59 11,222 3,4016 ,4447 
 The data show that mental functioning is less 
affected in men. Self-control, physical functioning, 
emotional control, and social integration are equally 
affected in women and men suffering from 
schizophrenia (Table 2). 
Table 2. SWN-S subscale „t” values according to gender 
 
Levene's Test for 
EVa 
t-test for Equality of Means 
F Sig. t df Sig. (2-
tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% CI of the Difference 
Lower Upper 
Mental 
functioning 
EVA 1,615 ,206 -2,032 141 ,044 -1,2855 ,6327 -2,5362 -,0347 
EVnA   -2,001 117,006 ,048 -1,2855 ,6424 -2,5576 -,0133 
Self-
control 
EVA 3,459 ,065 -1,954 141 ,053 -1,1880 ,6081 -2,3903 ,0142 
EVnA   -2,041 138,801 ,043 -1,1880 ,5820 -2,3388 -,0373 
Physical 
functioning 
EVA ,373 ,543 -1,119 141 ,265 -,8359 ,7468 -2,3123 ,6405 
EVnA   -1,134 129,372 ,259 -,8359 ,7369 -2,2938 ,6220 
Emotional 
regulation 
EVA 2,507 ,116 ,742 141 ,460 ,5880 ,7928 -,9793 2,1554 
EVnA   ,769 136,886 ,443 ,5880 ,7650 -,9246 2,1007 
Social 
integration 
EVA 7,954 ,005 -,956 141 ,341 -,6530 ,6831 -2,0035 ,6975 
EVnA   -1,001 139,152 ,319 -,6530 ,6526 -1,9433 ,6373 
 
1.2 SWN-S and type of schizophrenia 
The impact of the type of schizophrenia was tested 
on the quality of life using the 5 dimensions of the SWN-
S questionnaire. The data showed a significant 
difference between the types of schizophrenia on 3 of 
the 5 dimensions: mental functioning F (3,138)=2.81, 
p=0.042, emotional regulation F(3,138)=2.78, p=0.043 
and social integration F(3,138)=5.58, p=0.001. 
Post-hoc Bonferroni tests highlighted the fact that 
this difference was significant only for the social 
integration dimension: between the residual type of 
schizophrenia and the paranoid type of schizophrenia, 
hebephrenic type and undifferentiated type, in the case 
of the residual type, social integration level being 
significantly higher. This difference is further illustrated 
in Figure 1: 
 
Figure 1. Differences regarding social integration 
based on the type of schizophrenia 
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1.3 SWN-S and family history of psychiatric illness 
Variation in the quality of life was also tested across 
samples having different family histories of psychiatric 
illness. Mental functioning, self-control, and physical 
functioning were better preserved in patients who did 
not have a family history of psychiatric illness versus 
those who did (t(141)=2.43, p=.016), (t(141)=3.06, 
p=.003), (t(141)=2.94, p=.004) respectively. As for 
emotional regulation and the capacity of social 
integration, no significant differences were found: 
t(141) =1.6, p>.05 and t(141)=.94, p>.05 respectively.     
1.4 SWN-S and antipsychotic type 
Quality of life variation was tested across types of 
antipsychotic currently used. Analysis of variance 
showed significant differences on all 5 dimensions of 
SWN-S. Mental functioning was better maintained in 
the patients under treatment with atypical 
antipsychotics, versus the patients treated with typical 
antipsychotics (t (141)=4.01,p<.001).  
Self-control (t(141)=3.77,p=.001), physical 
function (t (141)=3.90, p=.001), emotional regulation (t 
(141) =3.12, p=.002), and social integration 
(t(141)=2.79, p=.006) were better preserved in patients 
who underwent treatment with atypical antipsychotics 
versus those treated with typical antipsychotics.  
2. Differential aspects of WHO-QoL-BREF 
2.1 Gender 
By analyzing the mean scores based on gender, it 
can be seen that male patients register higher scores for 
all WHO-Q0L-BREF dimensions compared to female 
patients (Fig. 2). 
 
Figure 2. Mean WHO-QoL scores based on 
gender (blue = female; red = male) 
Significant gender differences were obtained only 
for the Physical Health Dimension (T= -2,997, 
df=141,p<0,01) and Psychological Dimension (t=-
2,559, df=141, p<0,01).  
2.2 Type of Schizophrenia 
Patients suffering from undifferentiated 
schizophrenia registered the highest mean scores for all 
4 dimensions of the WHOQoL-BREF scale. The lowest 
mean scores were registered by patients diagnosed with 
hebephrenic schizophrenia on the Psychological and 
Environment dimensions, and by patients diagnosed 
with residual schizophrenia on the Physical health and 
Social relationships dimensions. However, ANOVA did 
not indicate statistically significant differences 
regarding schizophrenia type on these four dimensions: 
Physical health (f=0,949, df=3, p>0,05), Psychological 
(f=0,223, df=3, p>0,05), Social relationships (f=1,379, 
df=3, p>0,05) and Environment (f=1,117, df=3, 
p>0,05), based on the type of schizophrenia (Figure 3). 
 
2.3 Family history of psychiatric illness 
Analyzing the mean scores of the WHO-QoL – 
BREF scale, our study showed lower mean scores for 
Physical health, Psychological, and Environment 
dimensions, for patients who had a family history of 
psychiatric illness (Figure 4). 
 
Figure 4. Mean WHOQoL scores based on family 
history of psychiatric illness 
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Table 3. T test for separate lots– WHOQoL-BREF * Family history of psychiatric illness 
 
F Sig. t df Sig.  
(2-tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% CI of the 
Difference 
Lower Upper 
Mean 
EV 6.913 .010 2.103 141 .037 5.3360 2.5370 .3205 10.3515 
EVnA   1.972 92.898 .052 5.3360 2.7061 -.0378 10.7098    
Regarding the Social relationships dimension, 
although patients having a family history of psychiatric 
illness registered higher mean scores, the differences 
were not statistically significant (Table 3). 
2.4 Antipsychotic type:  
Regarding type of medication, higher mean scores 
were registered by the patients who followed a treatment 
plan with an atypical antipsychotic. However, a 
significant difference was observed only for the Social 
relationship dimension (Figure 5). 
 
Figure 5. Mean WHOQoL scores based on type of 
antipsychotics used 
Discussions 
Taking into consideration the chronic and 
debilitating characteristics of schizophrenia, a series of 
factors that influence quality of life have been studied 
by specialists in the field. Clinical characteristics, 
treatment related issues, and socio-demographical 
factors for a long time represented the main focus of 
researchers when discussing influences on quality of 
life. With the introduction of atypical antipsychotics 
which are able to control the positive symptoms (while 
presenting a low profile of major side effects), the focus 
on quality of life shifted from an objective perspective 
to a subjective one, represented by “the person’s sense 
of well-being and satisfaction with life” (25). The aim 
of the current study was to assess the impact of gender, 
type of schizophrenia, family history of psychiatric 
illness, and type of treatment administered on the 
perceived level of quality of life of patients suffering 
from schizophrenia.  
The association between gender and perceived level 
of quality of life had not been reported in many studies. 
In those studies, women generally had a lower degree of 
disability and a better quality of life. To explain these 
differences, the following hypotheses had been 
suggested: the later onset of the illness in female patients 
on one hand, and the more frequent occurrence of 
negative symptoms associated with behavioral problems 
in men (that may contribute to a higher level of 
deterioration of functioning in male patients), on the 
other hand (26-28). An alternative explanation for the 
differences of quality of life between men and women 
may be related to treatment response; female patients 
respond faster and also at lower doses, a result that could 
lead to better treatment compliance (29, 30). 
Overall, our study revealed better outcomes in male 
patients on all of the domains of the WHO-QoL – BREF 
score, while the SWN-S questionnaire showed a 
statistically significant difference only in the mental 
functioning domain. Our results contrast with those 
reported by Shtasel et al (on patients without 
medication) who concluded that women had a better 
quality of life than men, specifically in the social and 
relationship domains (31). Our findings using the WHO-
QoL – BREF score were similar to the results obtained 
of Yu-Tao Xiang and colleagues who showed that 
female patients suffering from schizophrenia had a 
lower quality of life than men who had the same illness 
(32). 
Many studies have shown the benefits of atypical 
antipsychotics regarding quality of life (33). Ritchie et 
al. (2003) revealed improvement in quality of life scores 
when switching from typical to atypical antipsychotics, 
specifically regarding olanzapine and risperidone 
administration (34). Voruganti et al. (2002) concluded 
that quality of life was improved for all patients who 
were switched to atypical antipsychotics, with no 
significant differences between the chosen antipsychotic 
(35). Our study reported higher quality of life regarding 
all domains analyzed by the two scales. Crossley et al. 
(2010) correlated better quality of life with a lower 
prevalence of extrapyramidal side effects when using 
atypical antipsychotics (36), providing a possible 
explanation for the results obtained in our study. 
Our results were consistent with those of Kilian and 
Angermeyer (2005) regarding mental functioning, 
which was better preserved in patients treated with 
atypical antipsychotics, but in contradiction with their 
other findings, as they found no significant differences 
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between patients treated with atypical antipsychotics 
and those treated with conventional ones concerning 
other domains of quality of life (37). 
Psychiatric symptoms were frequently perceived to 
have a negative impact on quality of life (38), but it was 
difficult to assess which had the largest influence; 
studies consistently have shown that negative symptoms 
have a greater effect on quality of life than positive 
symptoms (39-41). 
Our results are similar to those of Sigaudo et al 
(2014) which refer to the disorganization symptoms as a 
main factor leading to poor quality of life, especially in 
role-functioning and intrapsychic functioning domains 
(in our sample the hebephrenic type of schizophrenia 
registered the lowest scores in the Psychological and 
Environment dimensions) (42, 43). 
Study limitations: the number of patients included 
in the study was relatively low and patients were not 
equally distributed by gender (women being more than 
men), and these factors might have contributed to 
inconsistency of our results with other data from 
literature as well as diminished ability to generate to the 
population (44). Our sample consisted of patients under 
stable medication, so we did not assess the dynamic of 
switching from a typical antipsychotic to an atypical 
one. Our study was also performed without a control 
group.  
Conclusions 
This study revealed that mental functioning is better 
preserved in men, in patients who did not have a family 
history of psychiatric illness, and in patients who 
underwent treatment with atypical antipsychotics. In 
addition, the level of self-control and physical 
functioning is better for patients treated with atypical 
neuroleptics and who did not report a family history of 
psychiatric illness. Social integration is also better in 
patients who undergo treatment with atypical 
antipsychotics, but results vary depending on the type of 
schizophrenia, being significantly better in patients 
diagnosed with residual schizophrenia. 
By acknowledging factors that influence quality of 
life of patients with schizophrenia, we can further 
enhance our care/ therapeutic approach and increase the 
understanding of people who suffer from this disease.  
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